Solegear Bioplastics Inc.
TSX VENTURE : SGB

Solegear Bioplastics Inc.

July 29, 2015 08:30 ET

Solegear to Collaborate with Dr. Scholl's® on Bioplastic Packaging Solutions

Solegear's Proprietary Bioplastic Formulation to Help Achieve Sustainability Goals and Decrease Waste

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 29, 2015) - Solegear Bioplastic Technologies Inc. (the "Company") (TSX VENTURE:SGB) is pleased to be working with Dr. Scholl's® (owned by parent company, Bayer) - an iconic brand founded in 1906 and known world-wide for their foot care products - to collaboratively complete a production trial using Solegear's Traverse® (TF4000) bioplastic for use in the company's blister packaging applications.

"We are very excited about the potential to extend the reach of Solegear's proprietary bioplastics further into the North American consumer market and are honoured that such an iconic brand as Dr. Scholl's® is preparing to use our TF4000 formulation for their blister packaging applications," said Paul Antoniadis, Solegear CEO. "We are confident that our proven product will meet Dr. Scholl's® rigorous performance and durability requirements and help them meet their sustainability and waste reduction goals."

Solegear's Traverse® TF (TF4000) bioplastic formulation is designed to replace PET, PVC, RPET, and APET plastics and is known for its high heat resistance and clarity, making it an ideal material for packaging and global transport of consumer products. Composed of up to 46% plant-based content, Traverse® (TF4000) meets international shipping standards and can be recycled at the end of its life.

Antoniadis added: "The collaboration with Dr. Scholl's® is in line with Solegear's strategy to assist large U.S. corporations in making use of more sustainable products that contribute to meeting or exceeding their sustainability targets."

Solegear expects the production trial of Traverse® (TF4000) by Dr. Scholl's® to begin early fall, with potential manufacturing of packaging to begin in 2016.

About Solegear Bioplastic Technologies Inc.

Solegear Bioplastic Technologies Inc., based in Vancouver, British Columbia, is an innovator in the field of next-generation plastics. The Company is an advanced materials firm that engineers, produces and distributes high-performance bioplastics, a category of plastics that are bio-based, compostable, or both. Founded in 2006, Solegear has developed and is commercializing its proprietary formulas using annually renewable ingredients and green chemistry to address the growing North American market opportunity for rigid consumer packaging and durable plastic goods. www.solegear.ca

On behalf of the Company:

Paul Antoniadis, Chief Executive Officer and Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibilities for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws.

Implicit in this information, particularly in respect of potential manufacturing of packaging in 2016, is an assumption that Solegear's Traverse® TF (TF4000) bioplastic formulation will pass Dr. Scholl's® production trial and that Dr. Scholl's® will place a commercial order following such trial. This assumption, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. This forward looking information is subject to the risk that Dr. Scholl's® may not place a commercial order following its production trial.

Other than as required under securities laws, we do not undertake to update this information at any particular time.

Forward-looking information contained in this news release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. The reader should not place undue importance on forward-looking information and should not rely upon this information as of any other date. All forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement.

Contact Information